Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Dr. Reddy s Laboratories announces launch of India s first DCGI-approved Semaglutide injection Obeda® for Type 2 Diabetes.".
Press Release Mar 21 2026
Filed with NSE · · 4 pages · English
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings CallRelease
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
- Press Release Feb 18 2026
- Coya Therapeutics Announces $11.1 Million Private Placement
- Dr. Reddy's Laboratories: . Reddy’s Q3 & 9MFY26 Financial Results
- Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.
Later from Dr. Reddy's Laboratories
- Press Release Apr 24 2026
- Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
- Press Release May 12 2026
- Press Release May 16 2026
- Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories